A cross-over, randomised feasibility study of digitally printed versus hand-painted artificial eyes in adults: PERSONAL-EYE-S - a study protocol [version 1; peer review: awaiting peer review]

Taras Gout¹, Tim Zoltie², Amie Woodward³, Elizabeth Coleman³, Florien Boele⁴, Bernard Chang⁶, Paul Bartlett¹, Sarah Ronaldson³, George Kalantzis⁶, Mike Theaker⁷, Nabil El-Hindy⁶, Emma Walshaw¹, Judith Watson³

²School of Dentistry, Faculty of Medicine and Health, University of Leeds, Worsley Building, Leeds, LS2 9LU, UK
³York Trials Unit, Department of Health Sciences, University of York, York, YO10 5DD, UK
⁴Leeds Institute of Health Sciences, Faculty of Medicine and Health, University of Leeds, Leeds, LS2 9JT, UK
⁵Leeds Institute of Medical Research at St James's, St James's University Hospital, University of Leeds, Leeds, LS9 7TF, UK
⁶Department of Ophthalmology, Leeds Teaching Hospitals NHS Trust, Leeds, LS9 7TF, UK
⁷Patient and Public Involvement representative, Leeds, UK

Abstract
Background/objectives: Around 11,500 artificial eyes are required yearly for new and existing patients. Artificial eyes have been manufactured and hand-painted at the National Artificial Eye Service (NAES) since 1948, in conjunction with approximately 30 local artificial eye services throughout the country. With the current scale of demand, services are under significant pressure. Manufacturing delays as well as necessary repainting to obtain adequate colour matching, may severely impact a patient's rehabilitation pathway to a normal home, social and work life. However, advances in technology mean alternatives are now possible. The aim of this study is to establish the feasibility of conducting a large-scale study of the effectiveness and cost-effectiveness of digitally printed artificial eyes compared to hand-painted eyes.

Methods: A cross-over, randomised feasibility study evaluating a digitally-printed artificial eye with a hand-painted eye, in patients aged ≥18 years with a current artificial eye. Participants will be identified in clinic, via ophthalmology clinic databases and two charity websites. Qualitative interviews will be conducted in the later phases of the study and focus on opinions on trial procedures, the different artificial eyes, delivery times, and patient satisfaction.
Discussion: Findings will inform the feasibility, and design, of a larger fully powered randomised controlled trial. The long-term aim is to create a more life-like artificial eye in order to improve patients’ initial rehabilitation pathway, long term quality of life, and service experience. This will allow the transition of research findings into benefit to patients locally in the short term and National Health Service wide in the medium to long term.

**ISRCTN registration:** ISRCTN85921622 (17/06/2021)

**Keywords**
artificial eyes, feasibility, cross-over, qualitative, quality of life, health economics
Plain english summary

Aims of the research

A large-scale study is needed to see how traditional hand-painted artificial eyes compare with digitally-printed eyes in terms of patient satisfaction and cost. Before that, this smaller study is needed to show whether people would take part, are happy to provide health information, and learn what they liked and did not like about taking part.

Background to the research

After operations to remove a diseased or blind, painful eye many patients suffer from anxiety and depression. Returning to normal family, social and work life can be difficult. Artificial eyes have been hand-painted at the National Artificial Eye Service since 1948. Each eye takes over six weeks to make. Technology advances mean alternatives are now possible. A digital photograph of the unaffected eye printed onto a specialised paper and pressed onto the artificial eye is simpler and faster. Although the printed eye appears more life-like, there is no research evidence to show whether patients prefer it, the process can be done on a larger scale or save the National Health Service (NHS) money.

Design and methods

Thirty-five adults will be invited to participate. A computer will randomly select which artificial eye type (hand-painted or printed) they will receive first. After wearing the first eye for two weeks, they will wear the other type. Using questionnaires before and after wearing each eye, we will ask patients how satisfied they were with each eye, and how it affected their confidence and well-being. We will also interview some patients and family members to get a better understanding of their thoughts. We will also measure eye production times and costs.

Dissemination

Results will be presented at ophthalmology conferences. Study findings will be made available to participants, patient groups, NHS commissioners and reported on relevant patient-focused websites.

Introduction

The National Artificial Eye Service in England, UK has over 48,000 patients in its database alone and around 1,417 patients have surgery to remove their eye each year. Replacement artificial eyes are made every 2–6 years for adults, with around 11,500 artificial eyes required yearly for new and existing patients. These eyes are manufactured by the National Artificial Eye Service (NAES) in conjunction with around 30 local artificial eye services. With such a level of demand, services are under increasing pressure which can result in delays in provision of artificial eyes.

Following an operation to remove a diseased eye, such as for eye cancer, a well fitted, life-like artificial eye can help rehabilitation. However, many patients suffer from anxiety and depression associated with their perceived disfigurement, although the impact on Health-Related Quality of Life (HRQoL) is unknown.

The NAES has hand-painted artificial eyes since its integration into the National Health Service (NHS) in 1948. Local orbital prosthetists see patients in clinics, and use a non-standardised set of artificial eyes to colour match the appearance of the unaffected eye. A centralised site of laboratory technicians then manufacture the eye in six to ten weeks. However, achieving a good colour match is difficult and often requires multiple revisions.

This issue has been highlighted by Patient and Public Involvement (PPI) representatives as causing distress and delaying rehabilitation: many reported waiting up to 1 year for a good match. Family members or friends (hereafter called close contacts) are also impacted by the quality of artificial eyes as ill-matching eyes can cause distress. Digital photography for colour matching only the iris, and not the rest of the eye, have been described previously.

These issues prompted the novel design and development of digitally-printed artificial eyes by Leeds Artificial Eye Service (LAES), Leeds, UK. Early work demonstrated that patients can receive a more life-like match, often within 2 weeks and requiring fewer multidisciplinary clinic visits.

Further research has to determine whether digitally printed eyes result in improvements in patients’ HRQoL and satisfaction. A large-scale randomised controlled trial (RCT) is needed to evaluate the effectiveness and cost-effectiveness of digitally-printed compared to hand-painted artificial eyes in order to inform clinical practice. First, we will undertake a feasibility RCT to see if it is possible to conduct a larger study.

Study aims and objectives

The primary aim of this study is to determine the feasibility of conducting a RCT of the effectiveness and cost-effectiveness of digitally-printed artificial eyes compared to hand-painted eyes.

The specific objectives are to:

- Determine the eligibility rate;
- Determine patient recruitment rates;
- Identify retention rates, data fidelity and missing data;
- Identify a primary outcome measure(s) for a future trial (if feasibility established);
- Test study procedures and data collection tools and management;
- Establish scalability of the current service.

The feasibility of the future trial will be assessed based on whether:

- Patient recruitment and retention rates indicate recruitment for a full-scale RCT is plausible;
- Outcome measures and fidelity evaluation data are successfully collected. Measures with over 10% missing data may be modified/replaced prior to the main trial;
Qualitative data confirms willingness of patients to be recruited, randomised and find research processes acceptable; and healthcare professionals’ opinions on the different artificial eyes, views on delivery times and patient satisfaction proves acceptable.

Subjects and methods

Study design

The study is a single centre, cross-over, randomised controlled, open feasibility study. Eligible patients who provide written informed consent will be randomised to:

A: receive a digitally-printed artificial eye first (intervention), followed by a hand-painted artificial eye (control); or

B: receive a hand-painted artificial eye first, followed by a digitally-printed artificial eye.

A flow diagram demonstrating participant pathway through the study is provided in Figure 1. Participants will be asked to attend five clinics approximately 2 weeks apart. Clinic 1 – final eligibility, consent and baseline data; Clinic 2 – fitting of first eye; Clinic 3 – follow-up data on first eye; Clinic 4 – fitting of second eye; Clinic 5 – follow-up data on second eye and qualitative interviews.

All study documents including consent forms and data collection forms can be found as Extended data.

Setting

LAES at Leeds Teaching Hospitals NHS Trust will conduct participant identification, assess eligibility, consent participants and deliver the interventions.

Study population

Inclusion criteria

- aged ≥ 18 years old;
- longstanding artificial eye user (≥12 months post-operation);
- requires a replacement artificial eye;
- able to complete the English language outcome measures (independently or with assistance).

Exclusion criteria

- ongoing clinical concerns with respect to their artificial eye use (e.g. poor eye socket healing, extrusion, dehiscence);
- has bilateral artificial eyes;
- pregnant women or persons currently shielding (due to ongoing pandemic, to avoid unnecessary visits to clinic);
- currently participating in another study evaluating their artificial eye;
- unable or unwillingness to provide written informed consent.

Recruitment

Prospective participants will be identified via three main methods: in clinic, via database screening, or via notification placed on the Royal National Institute of Blind People and Blind Veterans UK websites.

Patients will be handed or posted a study invitation pack containing a Patient Invitation Letter, Participant Information Sheet, a Consent to Contact form, information pack for a close contact, and a pre-paid envelope. Patients will be asked to return the Consent to Contact form to York Trials Unit (YTU) if they wish to be contacted about the trial. Upon receipt of a patient’s Consent to Contact form, YTU will contact them to discuss any queries. The contact details of patients who are willing to be assessed for eligibility will be passed to LAES to arrange an appointment.

Eligibility and consent

Interested patients will be given an appointment to attend clinic for a final eligibility assessment.

Interested patients will be asked to approach a close contact (e.g. friend, family member, spouse), who might be willing to participate alongside the patient, in which case a specific information pack will be provided. Patients can take part without a close contact, but not vice versa.

If eligible and willing, written informed consent will be obtained from patients and, if applicable, their close contacts according to Good Clinical Practice guidelines.

Baseline assessment

Following consent procedures, baseline data will be collected according to the schedule in Table 1.

Eye history and assessment will include past medical history; past ocular and artificial eye history; current medications; and artificial eye socket examination (general socket health, fit and comfort of artificial eye, any current problems).

Randomisation

Following baseline data collection, an authorised team member at site will access a secure internet-based service hosted by the UKCRC-accredited YTU to obtain the order of the participant’s treatment allocation. Participants will be randomised on a 1:1 basis using block randomisation.

Level of masking

By the nature of the study treatments, masking of participants and clinic staff is not possible and procedure for un-masking is not necessary.

Study treatments

All participants will have an eye socket impression taken for a fitted artificial eye. The artificial eye shape will be made by the LAES maxillofacial laboratory.

Digitally printed artificial eye (Intervention): Digital photos of the unaffected eye will be printed onto specialised adhesive paper pressed onto the artificial eye.
Figure 1. Summary of patient/participant pathway.
Hand-painted artificial eye (Control): Colour matching the unaffected eye will be done by the imaging department using a colour guide. The artificial eye shape and colour guide number are then sent to iProsthetics (Norwich, UK), to hand-paint and encapsulate with acrylic the artificial eye.

Each eye will be worn for two weeks.

Data collection
A summary of all data collection is presented in Table 1.

Feasibility data
Data collected relating to recruitment will be: number and proportion of eligible patients: number approached for consent and not approached (and reason why); number approached who provide consent and do not provide consent (and reasons why). In addition, proportion of randomised participants withdrawing (with reasons) and lost to follow-up will be collected (and reason why, where possible).

Staff-collected data and preference questionnaire
Staff will collect data at baseline, Clinic 3 and Clinic 5 which will include information on eye socket health and adverse events (AEs). Data will also be collected at each clinic on tasks undertaken (including manufacturing steps both eyes) and time taken.

Following completion of the study by all participants, the healthcare professionals will also be asked to view eye-band images comparing both eyes, stating which they prefer.

Participant self-reported data
At baseline, Clinic 3 and Clinic 5 the following participant self-reported data will be collected:

---

Table 1. Baseline and follow-up data collection.

<table>
<thead>
<tr>
<th>Data</th>
<th>Timepoint</th>
<th>Baseline data (Clinic 1)</th>
<th>After first eye (Clinic 3)</th>
<th>After second eye (Clinic 5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligibility screening form</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Consent</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient reported:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographics</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>SF-36</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>VisQoL</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>EQ-5D-5L</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>CD-RISC-10</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>DAS-24</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Satisfaction</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Health care resource use</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Eye band image preference</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinician collected data</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical history</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye socket health and artificial eye check</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Adverse events</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Close contact data:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Satisfaction questionnaire</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye band image preference</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Semi-structured interviews with participants</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Semi-structured interviews with close contact</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Semi-structured interviews with healthcare professionals</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Healthcare professionals- eye band image preference</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
• Short Form 36 (SF-36): a generic HRQoL measure⁹.
• EQ-5D-5L (EuroQol-5 dimensions-5 levels): a generic HRQoL measure⁶.
• Vision Quality of Life Index (VisQol): assesses impact of vision loss⁹.
• Connor-Davidson Resilience Scale-10 (CD-RISC-10): provides a measure of resilience¹⁰.
• Derriford Appearance Scale short form (DAS24): assesses distress and difficulties in living with disfigurement
  and problems of appearance¹¹.
• Participant satisfaction: a brief study-specific questionnaire to assess participant satisfaction using a 0–10 scale.
  Eye-band image selection comparing both eyes will also be used.
• Resource use: a study-specific questionnaire on hospital attendances, admissions, and primary care visits (e.g.
  GP, nurse), in relation to their artificial eye.

Qualitative data collection

Qualitative interviews will be done in the later phases of the study and focus on opinions on trial procedures, the different artificial eyes, delivery times, and patient satisfaction. A subset of participants (approximately N=15), and their close contacts (approximately N=15) will be interviewed after both artificial eyes have been trialled. Interviews, lasting ~45 minutes, can be done face-to-face at a location of the person’s preference, over the phone, or via video-call and will be audio-recorded. Where possible, individual interviews will be conducted to allow each member of the dyad to freely express their feelings. Data collection will continue until saturation is achieved¹².

Approximately 5 members of the manufacture, ophthalmology, maxillofacial, and prosthetists teams will be invited to take part in a semi-structured interview lasting ~20 minutes. Following consent, interviews will take place face-to-face, over the phone or via videocall.

Close contact data

Close contacts will be asked to complete a study-specific satisfaction questionnaire after their friend/relative has worn each eye (Clinics 3 and 5) and asked to compare photographs of both eyes stating a preference (Clinic 5).

Attendance, follow-up and withdrawal

Appointments will be offered approximately 2–3 weeks apart. If a participant is unable to attend a scheduled appointment, they will be offered up to two further appointments within a 6-week period. They must attend Clinics 2 and 4 (the study eye fitting appointments) or will be withdrawn from the trial.

If the participant does not attend Clinics 3 or 5, they and their close contact will be mailed the follow-up questionnaire(s) by YTU. If not returned, they will receive a reminder letter followed by a telephone call.

Participants are free to withdraw from the study at any time and with no obligation to provide a reason. A participant may be withdrawn for clinical reasons. If a participant fully withdraws (i.e. withdraws from interventions, questionnaires and interview), their close contact is also withdrawn, but not vice versa.

Storage and confidentiality of data and patient records

Data will be collected through designed questionnaires identified by a unique participant trial number only. The research teams will hold data according to the General Data Protection Regulation (May 2018). Participant details will be stored on a secure password-protected server located at the University of York. Documents will be stored safely in confidential conditions, either physically or electronically and identifiable data will not be stored with questionnaire data. Qualitative interviews sound files and transcripts will be transferred onto a secure server and the data removed from the portable recording device. Data will be archived by the University of York for a minimum period of 5 years following the end of the study.

Adverse events

Adverse events (AEs) and serious AEs (SAEs) will be recorded. Intensity and relationship to the study intervention will be described. Examples of AEs related to participation in this study include: infection, inflammation and irrigation, pain/discomfort, prosthesis retention, and implant retention.

Ongoing review of AEs will take place during monthly trial management group (TMG) meetings, discussed with the patient advisory group (PAG) and trial steering committee (TSC) and reported to the sponsor and research ethics committee in line with their guidelines.

Sample size

As this is a feasibility study the primary outcome measure does not inform a sample size calculation. One of the study’s aims is to estimate the within-subject standard deviation for each outcome measure, in order to inform the sample size calculation for a future study. Pilot and feasibility trial literature recommends a sample size of between 24 and 70 to inform reliable estimation of standard deviations¹³,¹⁴. Thus, we aim to recruit 35 participants, which, assuming a 15% attrition rate, would allow for 30 participants in the final analysis.

Analyses

A statistical analysis plan detailing intended analyses will be drafted before the completion of data collection. The trial will be reported according to the CONSORT guidelines, including the extension to randomised cross-over trials¹⁵,¹⁶.

The number of patients screened, eligible, consented and randomised will be summarised. Baseline and outcome data, along with questionnaire return rates and adverse event data, will be summarised overall and by randomised group, and treatment period as appropriate. Within-subject differences for each outcome will also be summarised. To evaluate between-group change in outcome and process variables we will calculate the
mean and 95% confidence intervals at baseline, after trialing the first artificial eye, and after trialing the second artificial eye. We will report the number that receive each eye, by group. The number of participants who have a close contact will also be detailed, alongside the return rates for the close contact questionnaires, and associated outcomes.

Continuous variables will be summarised descriptively (mean, standard deviation, median, minimum and maximum) and categorical data will be summarised as counts and percentages. As this is a feasibility trial, statistical hypothesis testing for effectiveness will not be carried out.

The feasibility of undertaking an economic evaluation will be explored; relevant economic data will be identified and corresponding data collection methods investigated. Health outcomes (EQ-5D-5L), healthcare resource use, and costs for patients using the two artificial eye services will be evaluated using descriptive statistics similarly to those described above. Unit costs will be obtained from established costing sources\textsuperscript{10,19}, taking an NHS perspective. The cost of the eye services will be estimated to indicate the likely resource implications and corresponding costs. A full economic evaluation will not be conducted, though the health economics work, including exploration of missing economic data, will help guide the cost-effectiveness methods used in a full-scale trial.

Transcribed data from the qualitative interviews will be downloaded into NVivo software package, coded and analysed inductively using thematic content analysis\textsuperscript{20,21}. The researcher conducting the interviews will develop the initial coding framework of themes and subthemes. A second researcher will check a sample of data transcripts against the audio recordings, for accuracy, and will interrogate the validity of the coding against the raw data. The coding framework will be developed iteratively throughout the analysis process, through regular discussions leading to consensus. Detailed thematic summaries will be created using a flexible template that covers the research objectives, while allowing for the emergence of further themes.

Ethical and oversight arrangements
The TMG will monitor the day-to-day management of the trial. Due to the low risk nature of this trial, one independent steering and monitoring committee will set up to undertake the roles traditionally undertaken by the Trial Steering Committee (TSC) and Data Monitoring Committee. Ethical approval was granted by North West – Haydock on 09th June 2021 (Reference 21/NW/0150). The trial has been registered on ISRCTN (registration number: ISRCTN85921622) on 17th June 2021.

Patient and Public Involvement (PPI)
A PAG will contribute to study reports and disseminate findings at appropriate events.

The PAG will include at least four patient members and family members who will meet at critical time-points of the study (approximately every 4 months). Their role will include: assisting with the development of the satisfaction questionnaire; identifying barriers/facilitators to participation; identifying appropriate pathways for dissemination; contribute to the writing of the results lay summary; and, assisting with dissemination events. At least one member of the PAG will sit on the TMG.

Dissemination and projected outputs
Results will be written up and submitted to peer-reviewed journals and presented at relevant national/international ophthalmology conferences. Study findings will be made available to participants, PAG, NHS commissioners and reported on relevant patient-focused websites.

Study status
Data collection, eye manufacturing and clinic attendance are ongoing.

Conclusion
The aim of this study is to establish the feasibility of conducting a large-scale study of the effectiveness and cost-effectiveness of digitally-printed artificial eyes compared to hand-painted eyes. The impact will ultimately be realised by a larger fully powered randomised controlled trial, which this feasibility study will inform. The long-term aim is to create a more life-like artificial eye to improve patients’ initial rehabilitation pathway, long term quality of life, and service experience. This will allow the transition of research findings into benefit to patients locally in the short term and NHS wide in the medium to long term.

Data availability
Underlying data
No data are associated with this article.

Extended data
Open Science Framework: PERSONAL-EYEs. \url{https://doi.org/10.17605/OSF.IO/GWXUN}.

This project contains the following extended data:
- Consent forms
- Consent to Contact Forms
- Data Collection forms
- Participant Information Sheets

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

Acknowledgements
TSC Committee: Egle Rostron (Chair of Committee), Alex Wilkinson, Jianhua Wu, Paul Kirwan, and Luke Sansom.

Leeds Artificial Eye Service: Tom Archer (medical and dental photographer), Zoe Wilson (medical and dental photographer), Laura Lynch (senior ocular prosthetist), Jessica Kawalek (research assistant).

iProsthetics: Brett Flavell (director and chief ocularist).
References


